What is the appropriate treatment for a perimenopausal woman presenting with cognitive symptoms and anxiety but without vasomotor symptoms?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Treatment for Perimenopausal Cognitive Symptoms and Anxiety Without Vasomotor Symptoms

For perimenopausal women presenting with cognitive symptoms and anxiety but without vasomotor symptoms, hormone therapy (estrogen alone or estrogen plus progestogen) should be considered as first-line treatment, as perimenopausal depression and cognitive symptoms have a hormonal etiology and may not respond adequately to conventional antidepressants alone 1.

Rationale and Treatment Algorithm

Primary Consideration: Hormonal Etiology

Perimenopausal cognitive and mood symptoms represent a distinct syndrome driven by fluctuating gonadal hormones, not simply a gradual hormone deficiency 1. The neurochemical changes from hormonal fluctuations affect mood, cognition, and behavior in susceptible women, with psychological symptoms often appearing as the earliest signs of perimenopause—affecting up to 80% of women 1.

Key clinical point: Even without vasomotor symptoms, the underlying hormonal disruption can cause significant cognitive and anxiety symptoms. The absence of hot flashes does not exclude hormonal treatment as appropriate therapy.

Treatment Approach

Step 1: Establish Diagnosis and Baseline Risk

  • Confirm perimenopausal status through menstrual history patterns and, when indicated, replicate FSH and estradiol measurements 2
  • Assess cardiovascular disease risk, as this determines treatment selection 2
  • Use diagnostic tools like the Meno-D scale to identify perimenopausal depression 1

Step 2: Initiate Menopausal Hormone Therapy (if no contraindications)

For women without contraindications or excess cardiovascular/breast cancer risks 2:

  • Women without uterus: Estrogen therapy (ET) alone
  • Women with uterus: Estrogen plus progestogen therapy (EPT)

Cardiovascular risk stratification matters:

  • High CVD risk: Consider nonhormonal therapies first (see Step 3) 2
  • Moderate CVD risk: Use transdermal estradiol as first-line, combined with micronized progesterone for women with uterus, as these have fewer metabolic effects 2
  • Low CVD risk: Standard MHT preparations are appropriate 2

Critical caveat: Use only FDA-approved MHT preparations; avoid custom-compounded hormones 2. Employ shared decision-making regarding formulation, dose, and route 2.

Step 3: Nonhormonal Alternatives (if MHT contraindicated or declined)

When hormone therapy is inappropriate or unwanted, evidence supports:

SSRIs/SNRIs:

  • Venlafaxine 75 mg or escitalopram 10-20 mg showed comparable efficacy to estradiol for symptom relief in perimenopausal women 3
  • Paroxetine 7.5 mg daily improved symptoms without weight gain or sexual dysfunction 3
  • Important warning: Avoid fluoxetine and paroxetine in breast cancer patients on tamoxifen due to drug interactions 3

Gabapentin:

  • 900-1800 mg daily demonstrated efficacy over placebo for symptom relief and improved sleep 3
  • Side effects include dizziness (12.7%), headache (9.3%), and somnolence (6.0%), which typically improve after several weeks 3

Cognitive Behavioral Therapy:

  • CBT showed significant improvements in stress, anxiety, somatic and psychological symptoms, and sleep compared to psychoeducation alone 4
  • Combination approaches (pharmacotherapy plus psychotherapy) demonstrated superior outcomes across multiple psychological and endocrine measures compared to single-modality treatment 5

Adjunctive Interventions

Lifestyle and supportive measures should be addressed concurrently 2:

  • Bone health optimization
  • Cardiovascular risk management
  • Smoking cessation
  • Alcohol use assessment
  • Cancer screening

Psychotherapy integration: Trauma-informed psychotherapy should be considered as part of individualized treatment, particularly given the distinct hormonal etiology of perimenopausal depression 1.

Evidence Considerations and Nuances

The guideline evidence 2, 3 focuses primarily on vasomotor symptoms, but recent research 1 emphasizes that perimenopausal depression and cognitive symptoms represent a distinct syndrome that is "often not responsive to conventional antidepressant management" alone. This creates a clinical gap where hormone therapy may be appropriate even without classic hot flashes.

Divergent evidence note: While SSRIs/SNRIs showed comparable efficacy to estradiol in trials 3, these studies enrolled women with vasomotor symptoms. The 2026 research 1 specifically identifies perimenopausal depression as having a hormonal etiology requiring tailored treatment including MHT.

Monitoring and Safety

  • Review the decision to continue MHT at least annually 2
  • Target the shortest duration consistent with treatment goals 2
  • Inform patients about potential increased breast cancer risk with EPT and ensure age-appropriate screening 2
  • Evaluate any persistent unscheduled bleeding to rule out endometrial pathology 2

Common pitfall: Assuming that absence of vasomotor symptoms means hormone therapy is inappropriate. Cognitive and mood symptoms can be the predominant or sole manifestation of perimenopausal hormonal changes and may warrant hormonal treatment.

Related Questions

What are the causes and possible treatments for perimenopausal brain fog in a woman aged 45‑55?
What is an appropriate management plan for a 44-year-old woman with a history of anxiety who presents with bothersome perimenopausal symptoms (vaginal dryness, sleep disturbance, mood changes, palpitations, hot flashes, mental fogginess, occasional dizziness) and normal laboratory results?
What is the appropriate treatment for brain fog in a perimenopausal woman?
How should I manage a 47‑year‑old woman who is still menstruating but has menopausal symptoms, with progesterone 1.5 ng/mL, follicle‑stimulating hormone (FSH) 5.9 IU/L, luteinizing hormone (LH) 5.3 IU/L, estradiol 69 pg/mL, serum iron 46 µg/dL, ferritin 30 ng/mL, and normal thyroid function?
What is the appropriate management for a 48-year-old woman with perimenopausal symptoms who works two shifts?
Is a serum uric acid of 7 mg/dL a contraindication to initiating dapagliflozin 10 mg once daily in this patient?
Should a patient with a serum uric acid level of 7 mg/dL and no gout symptoms or urate‑related kidney stones be started on a uric‑acid‑lowering medication?
Should a patient with a positive direct Coombs test and anemia be referred to hematology?
What type of surgery is indicated for a patient with infective endocarditis and a mobile vegetation identified a month ago?
How many milliliters of the standard infant ibuprofen suspension (100 mg per 5 mL) are needed to deliver a 120 mg dose?
What are the recommended dosing guidelines, contraindications, and monitoring considerations for escitalopram (Lexapro) in adults and adolescents?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.